This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Astex Pharmaceuticals To Present At AACR-NCI-EORTC

DUBLIN, Calif., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced four presentations of developmental and collaboration programs will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 20 and 21, in Boston.
SGI-110 Abstract # A256  
Poster Presentation  Sunday, Oct. 20 12:30 - 7:30 p.m. EDT
Improved Antitumor Activity by Sequencing SGI-110 with CTLA-4 Blockade in a Syngenic Mouse Model
XIAP Abstract #A55  
Poster Presentation  Sunday, Oct. 20 12:30 - 7:30 p.m. EDT
Potent, dual cIAP1/XIAP antagonists induce apoptosis in a melanoma stem cell population
LEE011 Abstract #PR02  
Proffered Paper Session Sunday, Oct. 20 5:45 – 6 p.m. EDT
  Abstract #B264  
Novartis Poster Presentation Monday, Oct. 21 12:30 – 3 p.m. & 6:30 – 7:30 p.m. EDT
LEE011- An orally bioavailable, selective small molecule inhibitor of CDK4/6: Reactivating Rb in cancer
LEE011 Abstract #A276  
Novartis Poster Presentation Sunday, Oct. 20 12:30 - 3 p.m. & 6:30 – 7:30 p.m. EDT
Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas

Select posters will be made available for viewing on the Astex website .

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. Astex is developing a proprietary pipeline of novel therapies and is creating de-risked products for collaborations with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.92 0.30%
FB $117.75 -0.69%
GOOG $696.06 -0.31%
TSLA $235.00 -2.80%
YHOO $36.15 -1.00%


Chart of I:DJI
DOW 17,712.38 -178.78 -1.00%
S&P 500 2,060.31 -21.12 -1.01%
NASDAQ 4,763.1840 -54.41 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs